SCHEMBL1051979

SCHEMBL1051979

Fc1ccc(Oc2nc(-c3cn[nH]c3)cs2)nc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.42
GRM4 Q14833 1/20 0.42
MAPK14 Q16539 1/20 0.35
MAPK1 P28482 2/20 0.35
ROCK2 O75116 2/20 0.34
AKT1 P31749 1/20 0.34
AKT2 P31751 1/20 0.34
ALDH1A1 P00352 1/20 0.34
ALOX5 P09917 1/20 0.34
RAB9A P51151 1/20 0.34
NAMPT P43490 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.33
MAPK8 P45983 1/20 0.33
ILK Q13418 1/20 0.33
PDPK1 O15530 1/20 0.32
CYP19A1 P11511 2/20 0.32
KDM4E B2RXH2 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
CYP11B1 P15538 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1049256 0.81 GRM4 (0.57) KCNH2GRM4MAPK1AKT1AKT2
SCHEMBL1044551 0.79 MAPK14 (0.48) KCNH2GRM4MAPK14ROCK2ALDH1A1
SCHEMBL15049877 0.77 GRM4 (0.48) KCNH2GRM4MAPK1AKT1AKT2
SCHEMBL1052763 0.76 KCNH2 (0.43) KCNH2GRM4MAPK1ROCK2AKT1
SCHEMBL3706155 0.74 GRM4 (0.42) KCNH2GRM4MAPK1ROCK2AKT1
SCHEMBL30737880 0.72 AKT1 (0.48) MAPK1ROCK2AKT1AKT2MAPK8
SCHEMBL9977893 0.72 AKT1 (0.48) MAPK1ROCK2AKT1AKT2MAPK8
SCHEMBL370472 0.68 KCNH2 (0.58) KCNH2GRM4ROCK2ALDH1A1ALOX5
SCHEMBL29859845 0.66 KCNH2 (0.48) KCNH2GRM4MAPK1AKT1AKT2
SCHEMBL104535 0.65 AKT2 (0.61) ROCK2AKT1AKT2PDPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8513252-B2 Pyrazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors ADDEX PHARMA S.A. (CH) 2013-08-20 US claimed
EP-2456769-B1 NOVEL PYRAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA SA (CH) 2013-06-26 EP claimed
EP-2456769-A1 NOVEL PYRAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS Addex Pharma SA (CH) 2012-05-30 EP claimed
US-20120122907-A1 Novel Pyrazole Derivatives and their use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors NISSAN MOTOR CO., LTD. (JP) 2012-05-17 US claimed
US-8513252-B2 Pyrazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors ADDEX PHARMA S.A. (CH) 2013-08-20 US disclosed
EP-2456769-B1 NOVEL PYRAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA SA (CH) 2013-06-26 EP disclosed
EP-2456769-A1 NOVEL PYRAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS Addex Pharma SA (CH) 2012-05-30 EP disclosed
US-20120122907-A1 Novel Pyrazole Derivatives and their use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors NISSAN MOTOR CO., LTD. (JP) 2012-05-17 US disclosed
WO-2011010222-A1 NOVEL PYRAZOLE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2011-01-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122907-A1 Novel Pyrazole Derivatives and their use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors GRM1, GRM4, GRM3 KCNH2 1226/4885GRM4 2/4885MAPK14 1302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.